Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuPath HealthTSXV:NPTH 39 Altman Z-Score is 2.13 as of Aug. 28, 2026, which is 90% above its 10-year median of 1.12. GuruFocus rates TSXV:NPTH with a GF Score™ of 39/100 and a GF Value™ of C$0.25 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 656 Healthcare Providers & Services companies, NeuPath Health ranks worse than 55.49% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 2.15 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.
NeuPath Health has a Altman Z-Score of 2.13, indicating it is in Grey Zones. This implies that NeuPath Health is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for NeuPath Health's Altman Z-Score or its related term are showing as below:
TSXV:NPTH'
s Altman Z-Score Range Over the Past 10 Years
Min: 0.5 Med: 1.12 Max: 2.28
Current: 2.15
During the past 7 years, NeuPath Health's highest Altman Z-Score was 2.28. The lowest was 0.50. And the median was 1.12.
NeuPath Health (TSXV:NPTH) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
NeuPath Health Altman Z-Score Related Terms
NeuPath Health Altman Z-Score Historical Data
* Premium members only.
The historical data trend for NeuPath Health's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:NPTH vs HCA, THC, DVA: Altman Z-Score Comparison
For the Medical Care Facilities subindustry, NeuPath Health's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuPath Health Altman Z-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NeuPath Health's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where NeuPath Health's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
NeuPath Health's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.0482
+
1.4
*
-0.5487
+
3.3
*
0.0367
+
0.6
*
1.3531
+
1.0
*
1.9098
=
2.13
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
NeuPath Health (TSXV:NPTH) has a Altman Z-Score of 2.13 as of Aug. 28, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on NeuPath Health and its competitors. This is 90% above median its historical median of 1.12. Over the past decade, NeuPath Health's Altman Z-Score has ranged from 0.50 to 2.28. According to the industry distribution chart, NeuPath Health ranks #364 out of 656 companies in the Healthcare Providers & Services industry, placing it in the top 55.5%.
Is NeuPath Health's Altman Z-Score too high?
NeuPath Health's current Altman Z-Score of 2.13 is 90% above median its 10-year median of 1.12. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 2.28. The Healthcare Providers & Services industry median Altman Z-Score is 2.41. NeuPath Health's value of 2.13 is 11.6% below this industry median. Based on the distribution chart, NeuPath Health ranks #364 out of 656 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, NeuPath Health has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuPath Health's Altman Z-Score compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, NeuPath Health ranks #364 out of 656 companies for Altman Z-Score. This places NeuPath Health in the lower half of its industry. The industry median Altman Z-Score is 2.41. NeuPath Health's value of 2.13 is 11.6% below this benchmark. Historically, NeuPath Health's own Altman Z-Score has ranged from 0.50 to 2.28 over the past decade. While the company's 10-year median is 1.12 vs. the industry median of 2.41, NeuPath Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Healthcare Providers & Services company?
The median Altman Z-Score among Healthcare Providers & Services companies is 2.41, based on 656 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuPath Health's current Altman Z-Score of 2.13 is 11.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on NeuPath Health and its competitors. For the Healthcare Providers & Services industry, the median Altman Z-Score is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuPath Health's current Altman Z-Score is 2.13, which is 90% above median its own 10-year median of 1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuPath Health stock overvalued right now?
Based on GuruFocus' analysis, NeuPath Health (TSXV:NPTH) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.25, compared to a current price of C$0.55 — trading 120% above its estimated fair value. The current Altman Z-Score is 2.13, which is 90% above median its 10-year median of 1.12 and 11.6% below the Healthcare Providers & Services industry median of 2.41. NeuPath Health's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For NeuPath Health (TSXV:NPTH), the current Altman Z-Score is 2.13 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuPath Health (TSXV:NPTH) Overvalued in 2026?
Based on GuruFocus' analysis, NeuPath Health stock appears to be overvalued.
The current stock price of C$0.55 is trading 120% above its estimated GF Value™ of C$0.25.
GuruFocus considers NeuPath Health to be Significantly Overvalued.
Key valuation signals for TSXV:NPTH:
Altman Z-Score: 2.13 (90% above median its 10-year median of 1.12)
GF Value™: C$0.25 vs. price of C$0.55 (120% above fair value)
Industry Position: 11.6% below the Healthcare Providers & Services median (#364 of 656)
No single metric tells the full story. See the TSXV:NPTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuPath Health Inc operates an end-to-end, integrated network of healthcare businesses. It utilizes research, data-driven insights, technology, and interdisciplinary care to help restore function for patients impacted by acute and chronic musculoskeletal conditions, including chronic pain, spinal injuries, sports-related injuries, and concussions. It operates an interdisciplinary network of medical clinics in Ontario and Alberta, in addition to an independent medical assessment business with a national network of healthcare providers. Its medical clinics provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal or back injuries, sports-related injuries, and concussions. The company operates in one industry segment: medical services.
39GF Score
Get the complete analysis for TSXV:NPTH
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:NPTH has been successfully added to your 
